Efficacy and safety of stress ulcer prophylaxis in critically ill patients

Alhazzani, Waleed; Alshamsi, Fayez; Belley-Cote, Emilie; Heels-Ansdell, Diane; Brignardello-Petersen, Romina; Alquraini, Mustafa; Perner, Anders; Møller, Morten Hylander; Krag, Mette; Almenawer, Saleh; Rochwerg, Bram; Dionne, Joanna; Jaeschke, Roman; Alshahrani, Mohammed; Deane, Adam; Perri, Dan; Thebane, Lehana; Al-Omari, Awad; Finfer, Simon; Cook, Deborah; Guyatt, Gordon

Published in:
Intensive Care Medicine

DOI:
10.1007/s00134-017-5005-8

Publication date:
2018

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY-NC

Citation for published version (APA):
Alhazzani, W., Alshamsi, F., Belley-Cote, E., Heels-Ansdell, D., Brignardello-Petersen, R., Alquraini, M., ... Guyatt, G. (2018). Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials. Intensive Care Medicine, 44(1). https://doi.org/10.1007/s00134-017-5005-8

Download date: 05. Mar. 2020
Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials

Waleed Alhazzani1,2*, Fayez Alshamsi3, Emilie Belley-Cote2, Diane Heels-Ansdell2, Romina Brignardello-Petersen2, Mustafa Alquraini1, Anders Perner4, Morten Hylander Møller4, Mette Krag4, Saleh Almenawer5, Bram Rochwerg1,2, Joanna Dionne1, Roman Jaeschke1,2, Mohammed Alshahrani6, Adam Deane7, Dan Perri1, Lehana Thebane2, Awad Al-Omari8,9, Simon Finfer10, Deborah Cook1,2 and Gordon Guyatt1,2

© 2017 The Author(s). This article is an open access publication

Abstract

Purpose: Stress ulcer prophylaxis (SUP) is commonly prescribed in the intensive care unit. However, data from systematic reviews and conventional meta-analyses are limited by imprecision and restricted to direct comparisons. We conducted a network meta-analysis of randomized clinical trials (RCTs) to examine the safety and efficacy of drugs available for SUP in critically ill patients.

Methods: We searched MEDLINE, EMBASE, and the Cochrane Library Central Register of Controlled Trials through April 2017 for randomized controlled trials that examined the efficacy and safety of proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), and sucralfate for SUP in critically ill patients. No date or language restrictions were applied. Data on study characteristics, methods, outcomes, and risk of bias were abstracted by two reviewers.

Results: Of 96 potentially eligible studies, we included 57 trials enrolling 7293 patients. The results showed that PPIs are probably more effective for preventing clinically important gastrointestinal bleeding (CIB) than H2RAs [odds ratio (OR) 0.38; 95% confidence interval (95% CI) 0.20, 0.73], sucralfate (OR 0.30; 95% CI 0.13, 0.69), and placebo (OR 0.24; 95% CI 0.10, 0.60) (all moderate quality evidence). There were no convincing differences among H2RA, sucralfate, and placebo. PPIs probably increase the risk of developing pneumonia compared with H2RAs (OR 1.27; 95% CI 0.96, 1.68), sucralfate (OR 1.65; 95% CI 1.20, 2.27), and placebo (OR 1.52; 95% CI 0.95, 2.42) (all moderate quality). Mortality is probably similar across interventions (moderate quality). Estimates of baseline risks of bleeding varied significantly across studies, and only one study reported on Clostridium difficile infection. Definitions of pneumonia varied considerably. Most studies on sucralfate predate pneumonia prevention strategies.

Conclusions: Our results provide moderate quality evidence that PPIs are the most effective agents in preventing CIB, but they may increase the risk of pneumonia. The balance of benefits and harms leaves the routine use of SUP open to question.

Keywords: Stress ulcers, Critical illness, Network meta-analysis, Proton pump inhibitors, Pneumonia, Histamine-2 receptor antagonists, Sucralfate
Introduction
Stress ulcer prophylaxis (SUP) is usual practice in intensive care units (ICUs) worldwide. Across North America, Europe, and Australia, most patients with risk factors receive SUP during their ICU stay [1, 2]. A survey of 58 ICUs in North America showed that proton pump inhibitors (PPIs) are the most commonly used agents, followed by histamine-2 receptor antagonists (H2RAs); none of the participating centers used sucralfate or anti-acids [1]. A recent survey of 97 centers in Europe, Australia, and Canada yielded similar findings [3]. These practices reflect the results of systematic reviews of randomized controlled trials (RCTs) suggesting that H2RAs, compared with sucralfate or no prophylaxis, reduce the risk of gastrointestinal (GI) bleeding without increasing the risk of pneumonia, and that PPIs in comparison with H2RAs further reduce the risk of clinically important GI bleeding (CIB) without increasing pneumonia risk. The recommendations of the Surviving Sepsis Campaign guidelines are consistent with these results [4–6]. Nevertheless, concerns have grown regarding the magnitude of benefit of SUP, as well as the safety of acid suppressive therapy with respect to pneumonia, *Clostridium difficile* infection, cardiovascular events, and mortality [7]. Conventional meta-analyses are restricted to head-to-head comparisons, and therefore cannot inform on the relative merit of candidate therapies that have not been compared directly. By including indirect comparisons, network meta-analyses can not only address this limitation but also—by combining direct and indirect estimates—improve precision [8].

We therefore conducted a network meta-analysis addressing the relative impact of SUP with PPI, H2RAs, sucralfate, and placebo (or no prophylaxis) on overt CIB, pneumonia, *Clostridium difficile* infection, and death.

Methods
We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension statement for reporting network meta-analyses [Electronic Supplemental Material (ESM) Table 1] [9].

Data sources and searches
To identify RCTs comparing PPIs, H2RAs and sucralfate with one another and with placebo or no SUP in adult critically ill patients, we searched Cochrane CENTRAL, MEDLINE, and EMBASE from inception to April 2017 (ESM Table 2). We updated the search strategy for two systematic reviews of PPIs versus H2RA, and PPI versus placebo [6, 7], and conducted a complete search of the literature for other comparisons. We applied no restriction based on dose or route of drug administration or on language of publication. Eligible studies reported on at least one of the following: CIB, overt GI bleeding, pneumonia, mortality, and *Clostridium difficile* infection.

Study selection
Working in pairs, six reviewers screened citations and abstracts in duplicate and independently. The same pairs of reviewers evaluated all references judged potentially relevant for full-text eligibility.

Data extraction and quality assessment
Reviewers abstracted data in duplicate using piloted forms, and collected information on population demographics (age, sex, critical illness severity measure, ICU type, risk factors for bleeding), methodology and risk of bias, intervention and comparator (drug name, dose, route of administration, and duration of exposure), and outcomes. A third reviewer adjudicated disagreements not resolved by discussion.

We predefined CIB as evidence of upper GI bleeding with any of the following: significant hemodynamic changes not explained by other causes, need for transfusion of more than two units of blood, significant decrease in hemoglobin level, evidence of bleeding on GI endoscopy, or need for surgery to control the bleeding. Overt bleeding was defined as evidence of upper GI bleeding (hematemesis, melena, hematochezia, or coffee-gounds emesis or aspirate) regardless to other clinical findings. If an RCT only reported CIB, we considered all events as overt GI bleeding events. All studies used definitions consistent with those we prespecified.

We included pneumonia events in the ICU, whether or not they were associated with mechanical ventilation, accepting the definition used in each trial. We defined *Clostridium difficile* infection as a combination of clinical symptoms and a positive microbiologic test.

In duplicate, for each trial, reviewers assessed the risk of bias using the instrument recommended by the Cochrane Collaboration [10]. We provided a judgment of risk of bias as low (bias is not present or unlikely to alter the results seriously), unclear, or high (bias may seriously alter the results) for each of the following items: sequence generation, allocation sequence concealment, blinding of participants and clinicians, blinding of outcome assessment, incomplete outcome data assessment, and other bias. The overall risk of bias for each included trial was categorized as low if the risk of bias was low in all domains, unclear if the risk of bias was unclear in one or more domains and with no judgment of high risk of bias, or high if the risk of bias was high in one or more domains. We resolved disagreements by discussion.
Statistical analysis
Using a frequentist framework, we performed five random effects network meta-analyses, one for each outcome, calculating odds ratios (OR) and their corresponding 95% confidence intervals (CI). To evaluate inconsistency, we fit both a consistency and an inconsistency model for each outcome [11]. Using a node-splitting procedure [12], we calculated direct and indirect estimates for each pair of treatments. We calculated the frequentist analogue of the surface under the cumulative ranking curve (SUCRA) for each treatment (hereafter referred to as the SUCRA) [13]. All analyses were performed using the package mvmeta in Stata/IC 13.1 for Windows [14]. We assessed coherence (consistency) between direct and indirect estimates by performing node splitting and test for coherence [11]. We calculated the absolute treatment effect [risk difference (RD)] using the median event rate in the placebo arm in all trials for both clinically important GI bleeding and pneumonia outcomes. The median event rate in the placebo group was 2.1 and 6% for CIB and pneumonia outcomes, respectively.

Assessment of quality of evidence
For each outcome and each direct or indirect comparison, we applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the quality of evidence [15, 16]. For rating quality in each indirect comparison, we focused on the first-order loop with the smallest variance which, therefore, contributed the most to the estimate of effect. We assigned quality of the indirect comparison according to the contributing direct comparison (of the two) within each first-order loop with the lowest of the quality rating. We considered rating down the quality of evidence further when intransitivity (clinical heterogeneity) was present, analogous to rating down the quality of evidence in direct comparison meta-analysis for indirectness [17]. For network estimates of any paired comparison, we chose the highest quality rating amongst the direct and indirect comparisons. We rated down quality in the network estimate if incoherence between direct and indirect estimates was present. In a network meta-analysis, incoherence represents the differences between the direct and indirect estimates of effect, while heterogeneity is the differences in estimates of effect across studies that assessed the same comparison [17].

Role of the funding source
The funders of this study did not contribute to its design or conduction. The authors were entirely responsible for data collection, analysis, interpretation and reporting.

The corresponding author had access to all the data and final responsibility to submit for publication.

Results

Literature search
The initial search yielded 4139 citations; 93 proved potentially eligible after reviewing abstracts, of which 57 trials from 58 reports, representing 7293 patients, ultimately proved eligible (Fig. 1, ESM Table 2) [18–75].

Study characteristics
Of the 57 eligible trials, 18 compared PPIs with H2RAs; two, PPIs with sucralfate; four, PPIs with placebo; 18, H2RAs with sucralfate; 21, H2RAs with placebo; and six, sucralfate with placebo (ESM Figs. S1–S4). Trial sample size ranged from 28 to 1200 patients. Different doses, routes of administration, and durations of prophylaxis were used for PPIs and H2RAs across the trials (ESM Tables 3, 4).

Risk of bias
The risk of bias was high in 30 trials, low in 16 trials, and unclear in 11 trials (ESM Table 5).

Quality of evidence
Direct comparisons often suffered from limitations of risk of bias and imprecision. Regarding transitivity, although the intervention dosing and route varied across trials, the variation was not large enough to warrant concerns regarding intransitivity. Details can be found in Table 1 and ESM Table 5. For all comparisons across all outcomes, there was no statistical evidence of incoherence. Although no incoherence was detected by statistical testing, the test for incoherence could be underpowered; therefore, we further assessed incoherence by visually inspecting the direct and indirect estimates for any obvious differences. We considered problematic incoherence present for two comparisons based on visual inspection of direct and indirect estimates (Table 1).

The quality of evidence of network estimates for various comparisons across all outcomes ranged from low to moderate (Table 1).

Clinical outcomes
Clinically important GI bleeding
Thirty-one RCTs (5283 patients) reported on CIB [21, 25, 26, 30–32, 35, 36, 38–40, 42–44, 46–48, 57–59, 61, 63–67, 69–72, 74]. For three comparisons, the network estimate provided moderate-quality evidence with a CI excluding 1.0: PPIs versus H2RAs (OR 0.38; 95% CI 0.20, 0.73), PPIs versus no prophylaxis or placebo (OR 0.24; 95% CI 0.10, 0.60), and PPIs versus sucralfate (OR 0.30; 95% CI 0.13, 0.69). (Table 1, Fig. 2a). The SUCRA statistic showed that
PPIs ranked first, followed by H2RAs, sucralfate, and placebo (ESM Table 6, Fig. 3a).

**Pneumonia**
Thirty-five RCTs (5452 patients) reported on pneumonia [18, 19, 21, 22, 25, 26, 28–30, 32, 36, 37, 39–42, 44, 46–49, 51–54, 57, 58, 60, 61, 65–68, 70, 71]. PPIs ranked last compared with other interventions in terms of risk of pneumonia (ESM Table 7, Fig. 3b). Network meta-analysis results showed that PPIs and H2RAs probably increase the risk of pneumonia compared with sucralfate (OR 1.65; 95% CI 1.20, 2.27; moderate quality), and placebo or no prophylaxis (OR 1.07; 95% CI 0.74, 1.56; moderate quality). H2RAs were superior to no prophylaxis in reducing risk of overt GI bleeding (OR 0.42; 95% CI 0.28, 0.63; moderate quality), but not sucralfate (OR 1.05; 95% CI 0.69, 1.59; moderate quality) (ESM Table 8 and Fig. S6). PPIs ranked first in reducing overt bleeding compared with other agents (ESM Table 9, Fig. S7).

**Mortality**
Thirty-six RCTs (5498 patients) reported on mortality [18, 19, 21, 23–25, 26, 28, 29, 31, 34–40, 44, 46–51, 53, 56, 59–62, 64–66, 68–71, 75]. The results provide moderate-quality evidence that there is no difference between any of the management options in terms of all-cause mortality (Table 1, ESM Fig. S5). Given that all estimates were similar and approximated no effect, we did not calculate SUCRA values for the mortality outcome.

**Clostridium difficile infection**
Only one trial reported *Clostridium difficile* infection; therefore, we could not provide a network estimate for this outcome [66].

**Overt GI bleeding**
For overt GI bleeding, 49 studies (6662 patients) proved eligible [18, 20, 21, 23–36, 38–40, 42–75]. PPIs were superior to H2RAs (OR 0.34; 95% CI 0.19, 0.60, moderate quality), sucralfate (OR 0.35; 95% CI 0.18, 0.71, moderate quality), and placebo or no prophylaxis (OR 0.14; 95% CI 0.07, 0.28, moderate quality). H2RAs were superior to no prophylaxis in reducing risk of overt GI bleeding (OR 0.42; 95% CI 0.28, 0.63, moderate quality), but not sucralfate (OR 1.05; 95% CI 0.69, 1.59, moderate quality) (ESM Table 8 and Fig. S6). PPIs ranked first in reducing overt bleeding compared with other agents (ESM Table 9, Fig. S7).

**Discussion**
In this network meta-analysis, we included 57 RCTs enrolling 7293 patients comparing various SUP strategies. SUP with either PPIs or H2RAs likely reduces CIB (moderate quality evidence) (Table 1) relative to not using prophylaxis, and PPIs are likely superior to both H2RAs and sucralfate. Given the current estimates of the frequency of CIB, the magnitude of benefit is not large.

On the other hand, PPIs likely result in a higher risk of pneumonia than other prophylaxis regimens or no prophylaxis (moderate-quality evidence) (Table 1). These results are consistent with indirect evidence from multiple observational studies that have reported an increased risk of community- and hospital-acquired pneumonia in patients using PPIs [76–78]. Further direct supporting evidence comes from a retrospective observational study that reported a higher risk of pneumonia in critically ill patients on PPIs than for those on H2RAs in the ICU [79].

Low-quality evidence suggests that sucralfate may reduce pneumonia in comparison with placebo. This finding—together with the moderate-quality evidence of a lower pneumonia risk with sucralfate than PPIs—is consistent with prior physiologic and microbiologic data establishing the antibacterial effect of sucralfate, independently of the gastric pH level [80–82]. If the point estimate for pneumonia is accurate, PPIs relative to no SUP would result in a substantial increase in pneumonia.
The use of indirect comparisons within this network meta-analysis adds additional information beyond the multiple direct comparison meta-analyses that have compared PPIs, H2RAs, and sucralfate with placebo and with one another [6, 7, 83–87]. First, moderate-quality indirect evidence supports the previously observed effect of PPIs decreasing CIB relative to no SUP and relative to other agents (Table 1). Second, our results provide additional moderate quality evidence in support of the hypothesis that PPIs may increase the incidence of pneumonia relative to H2RAs, to sucralfate, and to no SUP. Prior systematic reviews were limited by imprecision and by the small number of studies for some direct comparisons, such as PPIs and placebo. Network meta-analytic techniques allowed us to generate more reliable estimates for these comparisons, particularly for the pneumonia outcome.

Table 1 Direct, indirect and network meta-analysis estimates of the odds ratios of the effects of different prophylaxis comparisons

| Comparison | RCTs | Direct estimate (95% CI) conventional MA | Direct estimate (95% CI) from node splitting | Quality | Indirect estimate (95% CI) | Quality | NMA estimate (95% CI) | Quality |
|------------|------|------------------------------------------|---------------------------------------------|--------|---------------------------|---------|----------------------|---------|
| Clinically important bleeding | | | | | | | | |
| H2RA vs placebo | 7 | 0.52 (0.21, 1.33) | 0.53 (0.23, 1.19) | Moderate | 1.36 (0.29, 6.51) | Low | 0.64 (0.32, 1.30) | Moderate |
| PPI vs H2RA | 14 | 0.37 (0.20, 0.68) | 0.35 (0.18, 0.69) | Moderate | 0.86 (0.11, 7.02) | Low | 0.38 (0.20, 0.73) | Moderate |
| H2RA vs sucralfate | 12 | 0.79 (0.49, 1.27) | 0.86 (0.48, 1.55) | Moderate | 0.32 (0.04, 2.67) | Low | 0.80 (0.46, 1.40) | Moderate |
| PPI vs placebo | 4 | 0.67 (0.12, 3.59) | 0.66 (0.12, 3.74) | Low | 0.17 (0.06, 0.49) | Moderate | 0.24 (0.10, 0.60) | Moderate |
| Sucralfate vs placebo | 4 | 1.13 (0.44, 2.90) | 1.15 (0.41, 3.23) | Low | 0.48 (0.14, 1.64) | Moderate | 0.80 (0.37, 1.73) | Low |
| PPI vs sucralfate | 1 | 0.31 (0.03, 3.05) | 0.23 (0.02, 2.30) | Low | 0.32 (0.13, 0.76) | Moderate | 0.30 (0.13, 0.69) | Moderate |
| Pneumonia | | | | | | | | |
| H2RA vs placebo | 8 | 1.11 (0.61, 2.00) | 1.09 (0.70, 1.71) | Moderate | 1.94 (0.73, 5.20) | Low | 1.19 (0.80, 1.78) | Moderate |
| PPI vs H2RA | 13 | 1.15 (0.83, 1.59) | 1.15 (0.85, 1.57) | Moderate | 2.10 (1.04, 4.21) | Moderate | 1.27 (0.96, 1.68) | Moderate |
| H2RA vs sucralfate | 16 | 1.36 (1.03, 1.79) | 1.32 (0.98, 1.77) | Moderate | 1.35 (0.64, 2.86) | Low | 1.30 (1.08, 1.58) | Moderate |
| PPI vs placebo | 3 | 1.53 (0.56, 4.16) | 1.48 (0.55, 3.99) | Low | 1.53 (0.90, 2.59) | Moderate | 1.52 (0.95, 2.42) | Moderate |
| Placebo vs sucralfate | 4 | 0.65 (0.34, 1.26) | 0.67 (0.34, 1.32) | Low | 1.54 (0.84, 2.80) | Moderate | 1.09 (0.72, 1.66) | Low |
| PPI vs sucralfate | 4 | 2.37 (1.28, 4.42) | 2.16 (1.24, 3.77) | Low | 1.44 (0.97, 2.14) | Moderate | 1.65 (1.20, 2.27) | Moderate |
| Mortality | | | | | | | | |
| H2RA vs placebo | 17 | 0.95 (0.71, 1.26) | 0.95 (0.73, 1.25) | Moderate | 1.04 (0.62, 1.73) | Moderate | 0.97 (0.77, 1.23) | Moderate |
| H2RA vs PPI | 11 | 0.86 (0.63, 1.17) | 0.86 (0.63, 1.17) | Moderate | 0.75 (0.41, 1.37) | Moderate | 0.83 (0.63, 1.10) | Moderate |
| Sucralfate vs H2RA | 12 | 0.95 (0.79, 1.16) | 0.95 (0.78, 1.15) | Moderate | 1.17 (0.53, 2.62) | Moderate | 0.96 (0.79, 1.16) | Moderate |
| Placebo vs PPI | 4 | 0.77 (0.47, 1.24) | 0.77 (0.47, 1.24) | Moderate | 0.94 (0.61, 1.44) | Moderate | 0.86 (0.62, 1.18) | Moderate |
| Sucralfate vs placebo | 6 | 0.98 (0.66, 1.47) | 0.99 (0.66, 1.49) | Moderate | 0.88 (0.60, 1.28) | Moderate | 0.93 (0.71, 1.23) | Moderate |
| Sucralfate vs PPI | 1 | 0.96 (0.42, 2.23) | 0.96 (0.41, 2.22) | Low | 0.77 (0.55, 1.10) | Moderate | 0.80 (0.58, 1.10) | Moderate |

CI confidence interval, H2RA histamine 2 receptor antagonists, MA meta-analysis, NMA network meta-analysis, PPI proton pump inhibitors, RCTs randomized controlled trials

a Quality of evidence for direct estimate rated down by one level for serious imprecision
b Quality of evidence for direct estimate rated down by two levels for very serious imprecision
c Quality of evidence for direct estimate rated down by one level for serious risk of bias
d We did not downgrade for intransitivity in any of the indirect comparisons
\* Quality of evidence for indirect estimate rated down by two level for very serious imprecision
f Quality of evidence for indirect estimate rated down by one level for serious imprecision
\* Quality of evidence for indirect estimate was rated down by one level for risk of bias
h Quality of evidence for network estimate rated down by one level for serious imprecision
i Quality of evidence for network estimate rated down by one level for serious incoherence
j Quality of evidence for network estimate rated down by one level for serious risk of bias
Comparison Odds Ratio (95% CI)

H2RA vs Placebo
- Direct: 0.53 (0.23, 1.19)
- Indirect: 1.36 (0.29, 6.51)
- Network: 0.64 (0.32, 1.30)

PPI vs H2RA
- Direct: 0.35 (0.18, 0.69)
- Indirect: 0.86 (0.11, 7.02)
- Network: 0.38 (0.20, 0.73)

H2RA vs Sucralfate
- Direct: 0.86 (0.48, 1.55)
- Indirect: 0.32 (0.04, 2.67)
- Network: 0.80 (0.46, 1.40)

PPI vs Placebo
- Direct: 0.66 (0.12, 3.74)
- Indirect: 0.17 (0.06, 0.49)
- Network: 0.24 (0.10, 0.60)

Sucralfate vs Placebo
- Direct: 1.15 (0.41, 3.23)
- Indirect: 0.48 (0.14, 1.64)
- Network: 0.80 (0.37, 1.73)

PPI vs Sucralfate
- Direct: 0.23 (0.02, 2.30)
- Indirect: 0.32 (0.13, 0.76)
- Network: 0.30 (0.13, 0.69)

Test for inconsistency: $p = 0.889$ (indicating not inconsistent).

Fig. 2  

a Clinically important bleeding outcome.  
b Pneumonia outcome.

**Comparison Odds Ratio (95% CI)**

H2RA vs Placebo
- Direct: 1.09 (0.70, 1.71)
- Indirect: 1.94 (0.73, 5.20)
- Network: 1.19 (0.80, 1.78)

PPI vs H2RA
- Direct: 1.15 (0.85, 1.57)
- Indirect: 2.10 (1.04, 4.21)
- Network: 1.27 (0.96, 1.68)

H2RA vs Sucralfate
- Direct: 1.32 (0.98, 1.77)
- Indirect: 1.35 (0.64, 2.86)
- Network: 1.30 (1.08, 1.58)

PPI vs Placebo
- Direct: 1.48 (0.55, 3.99)
- Indirect: 1.53 (0.90, 2.59)
- Network: 1.52 (0.95, 2.42)

Placebo vs Sucralfate
- Direct: 0.67 (0.34, 1.32)
- Indirect: 1.54 (0.84, 2.80)
- Network: 1.09 (0.72, 1.66)

PPI vs Sucralfate
- Direct: 2.16 (1.24, 3.77)
- Indirect: 1.44 (0.97, 2.14)
- Network: 1.65 (1.20, 2.27)

Test for inconsistency: $p = 0.794$ (indicating not inconsistent). CI confidence interval, H2RA histamine 2 receptor antagonists, PPI proton pump inhibitors.
Conventional meta-analyses are restricted to direct comparisons and do not consider indirect evidence in situations where evidence is sparse.

We have thus far focused on estimates of relative effects. In considering the implications of our results for use of SUP, consideration of absolute effects is crucial. The best estimates of the impact of PPIs on CIB suggest an absolute reduction of 1.6% relative to placebo, with a CI of 0.8–1.9% (Table 2). Similar estimates for pneumonia suggest an absolute increase of 3.1%, with a CI ranging from 0.3% fewer events to 8.5% more events. These estimates raise serious questions about the net benefit of PPIs for SUP.

The strengths of this work include a comprehensive search, duplicate review of trial eligibility and risk of bias, and adherence to the PRISMA guidelines for reporting network meta-analyses (ESM Table 1) [9]. We adopted a frequentist (likelihood maximization) rather than a Bayesian approach to combine the results, avoiding issues relating to pre-specification of variance [88]. We used the node-splitting technique to provide estimates of indirect evidence, and applied the GRADE approach to assess the

---

**Fig. 3** a Cumulative ranking curve for clinically important bleeding outcome. CIB clinically important bleeding, H2RA histamine 2 receptor antagonists, PPI proton pump inhibitors. b Cumulative ranking curve for pneumonia outcome. H2RA histamine 2 receptor antagonists, PPI proton pump inhibitors.
quality of evidence for each outcome, including specification of quality of direct, indirect, and network estimates [15]. To enhance the generalizability of our results, we included studies of patients with a wide spectrum of critical illness. We used best current estimates of effect for baseline risk to derive likely absolute effects of SUP on serious bleeding and pneumonia.

This study also has limitations. Although most RCTs used microbiological, radiological and clinical criteria to diagnose pneumonia, there was considerable variation in definitions [89]. Estimates of baseline risk vary appreciably across trials. In addition, most trials examining sucralfate predate the effective pneumonia prevention strategies, attenuating the applicability of these results to current practice. Only one trial addressed Clostridium difficile infection, which is important given a recent 30,000-patient retrospective observational study suggesting that PPIs may increase the risk of Clostridium difficile colitis [90]. Furthermore, the majority of trials did not report on nutritional management, which limited our ability to examine the effect of enteral nutrition as an effect modifier.

The universal use of SUP should be reconsidered in the light of uncertain net benefit. Two large multicenter RCTs are ongoing, the SUP-ICU in Europe (clinicaltrials.gov registration NCT02467621) and the REVISE Trial in North America, Australia, and Saudi Arabia. The results of these trials will provide further information about the safety of withholding stress ulcer prophylaxis in the ICU.

**Conclusion**

Our results provide moderate-quality evidence that PPIs are the most effective prophylactic strategy for SUP, with an absolute risk reduction in CIB relative to no prophylaxis of 1.6%. The benefit of PPIs must, however, be weighed against the risk of pneumonia, and possibly of Clostridium difficile infection. Moderate-quality evidence provides a best estimate of the increase in pneumonia with PPIs relative to no prophylaxis of over 3%. These estimates raise serious questions regarding the net benefit of SUP and its widespread use. The findings of this network meta-analysis can inform clinicians who consider the local incidence of CIB, pneumonia, and Clostridium difficile infection when deciding on uniform, selective, or sparing use of SUP in critically ill patients.

**Table 2 Absolute treatment effect for clinically important bleeding and pneumonia outcomes**

| Comparison | RD per 1000 patients (95% CI) for ACR | Number needed to treat |
|------------|--------------------------------------|------------------------|
| H2RA vs placebo | 8 fewer per 1000 (6 more to 14 fewer) | 13 |
| PPI vs H2RA | 8 fewer per 1000 (from 4 fewer to 10 fewer) | 13 |
| H2RA vs sucralfate | 3 fewer per 1000 (from 7 more to 9 fewer) | 33 |
| PPI vs placebo | 16 fewer per 1000 (from 8 fewer to 19 fewer) | 6 |
| Sucralfate vs placebo | 4 fewer per 1000 (from 13 fewer to 15 more) | 25 |
| PPI vs sucralfate | 12 fewer per 1000 (from 6 fewer to 15 fewer) | 8 |

**Pneumonia outcome**

| Comparison | RD per 1000 patients (95% CI) for ACR | Number needed to harm |
|------------|--------------------------------------|----------------------|
| H2RA vs placebo | 11 more per 1000 (from 12 fewer to 42 more) | 9 |
| PPI vs H2RA | 19 more per 1000 (from 3 fewer to 48 more) | 5 |
| H2RA vs sucralfate | 17 more per 1000 (from 4 more to 32 more) | 5 |
| PPI vs placebo | 31 more per 1000 (from 3 fewer to 85 more) | 3 |
| Placebo vs sucralfate | 5 more per 1000 (from 15 fewer to 36 more) | 20 |
| PPI vs sucralfate | 36 more per 1000 (from 11 more to 70 more) | 3 |

RD risk difference, ACR assumed control event rate, H2RA histamine-2 receptor antagonists, PPI proton pump inhibitor, GI gastrointestinal

a The median event rate of clinically important bleeding across all trials in placebo arm was 2.1%

b The median event rate of pneumonia across all trials in placebo arm was 6%

**Electronic supplementary material**

The online version of this article (https://doi.org/10.1007/s00134-017-5005-8) contains supplementary material, which is available to authorized users.

**Author details**

1 Division of Critical Care, Department of Medicine, McMaster University, St Joseph’s Healthcare Hamilton, 50 Charlton Avenue, Hamilton, ON L8N 4A6, Canada. 2 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada. 3 Department of Internal Medicine, College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates. 4 Department of Intensive Care, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 5 Department of Surgery, McMaster University, Hamilton, Canada. 6 Department of Critical Care, Dammam University, Dammam, Saudi Arabia. 7 Discipline of Acute Care Medicine, University of Adelaide, Adelaide, Australia. 8 Department of Critical Care, Security Forces Hospital, Riyadh, Saudi Arabia. 9 Department of Medicine, Alfaisal University, Riyadh, Saudi Arabia. 10 The George Institute for Global Health and Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.
Compliance with ethical standards

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Funding

This study was funded by the Hamilton Chapter of the Canadian Intensive Care Foundation, the Critical Care Medicine Residency Program, and the Critical Care Division Alternate Funding Plan at McMaster University. Waleed Alhazzani holds a McMaster University Department of Medicine Internal Career Research Award. Deborah Cook is a Canada Research Chair of the Canadian Institutes for Health Research.

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Received: 23 July 2017 Accepted: 24 November 2017 Published online: 4 December 2017

References

1. Barletta JT, Kanji S, MacLaren R, Lat I, Erstad BL, American–Canadian consortium for Intensive Care Drug Utilization I (2014) Pharmacoeconomics of stress ulcer prophylaxis in the United States and Canada. J Crit Care 29:955–960
2. Krag M, Perren A, Weterssler J, Wise MP, Borthwick M, Bendel S, McArthur C, Cook D, Nielsen N, Pelosi P, Keus F, Guttmann AB, Moller AD, Moller MH, Co-authors S-I (2015) Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. Intensive Care Med 41:833–845
3. Krag M, Perren A, Weterssler J, Wise MP, Borthwick M, Bendel S, McArthur C, Cook D, Nielsen N, Pelosi P, Keus F, Guttmann AB, Moller AD, Moller MH, Collaborators S-I (2015) Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries. Acta Anaesthesiol Scand 59:576–585
4. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deuschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric S (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
5. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Fessler R, Kumar A, Servan‑Katz E, Sprung CL, Nunnally ME, Rochberg W, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellomo R, Brown R, Chiche J‑D, Cooper‑Simmons C, Darouiche OR, De Backer DP, French CF, Fujishita S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AM, Klauser P, Knaus WA, McDonald T, Lichtenstein R, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deuschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric S (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. J Crit Care 28:1–26
6. Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ (2013) Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med 41:693–705
7. Krag M, Perren A, Weterssler J, Wise MP, Hylander Moller M (2014) Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med 40:11–22
8. Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23:3105–3124
9. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thurlow K, Jansen JP, Mulrow C, Calsavara P, Gotzsche PC, Dickersin K, Bouter L, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta‑analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777–784
10. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schuit KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Sta‑tistical Methods G (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
11. White IR, Barrett JK, Jackson D, Higgins JP (2012) Consistency and inconsist‑ency in network meta‑analysis: model estimation using multivariate meta‑regression. Res Synth Methods 3:111–125
12. Dias S, Welton NJ, Caldwell DM, Ades AE (2010) Checking consistency in mixed treatment comparison meta‑analysis. Stat Med 29:932–944
13. Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple‑treatment meta‑analysis: an overview and tutorial. J Clin Epidemiol 64:163–171
14. White IR (2009) Multivariate random‑effects meta‑analysis. Stata J 9:40–56
15. Balsbhm H, Hefland M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck‑Ytter Y, Meerpohl JN, Norris S, Guyatt GH (2011) GRADE guide‑lines: 13. Rating the quality of evidence. J Clin Epidemiol 64:401–406
16. Puhani MA, Schunemann HJ, Murad MH, Li T, Brigardelli‑Petersen R, Singh JA, Kessels AG, Guyatt GH, Group GW (2014) A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta‑analysis. BMJ 349:g5630
17. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Hefland M, Alonso‑Coello P, Falck‑Ytter Y, Jaeschke R, Vist G, Akl EA, Post PN, Norris S, Meerpohl JN, Shukla VK, Nasser M, Schunemann HJ, Group GW (2011) GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin Epidemiol 64:1303–1310
18. Apte NM, Karnad DR, Medhekar TP, Tilve GH, Morey S, Bhave GG (1992) Gastric colonization and pneumonia in intubated critically ill patients receiving stress ulcer prophylaxis: a randomized, controlled trial. Crit Care Med 20:590–593
19. Bashar FR, Manuchoheiran N, Mahmoudabadi M, Haji‑Msaeli MR, Torabani S (2013) Effects of ranitidine and pantoprazole on ventilator‑associated pneumonia: a randomized double‑blind clinical trial. Tаниfaxes: 12:16–21
20. Basso N, Baragani M, Materia A, Fiorani S, Lundani R, Speranzan V (1981) Cimetidine and antacid prophylaxis of acute upper gastrointestinal bleeding in high risk patients. Controlled, randomized trial. Am J Surg 143:339–343
21. Ben‑Menachem T, Fogel R, Patel RV, Touchette M, Zarowitz BJ, Haddadija N, Divine G, Verter J, Bresalier RS (1994) Prophylaxis for stress‑related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single‑blind study. Ann Intern Med 121:568–575
22. Bhanoit RD (2010) Nosocomial pneumonia in mechanically ventilated patients receiving ranitidine, omeprazole or sucralfate as stress ulcer prophylaxis. American Thoracic Society International Conference, ATS 2010 New Orleans 181 (1 Meeting Abstracts)
23. Burgess P, Larson GM, Davidson P, Brown J, Metz CA (1995) Effect of ranit‑idine on intragastric pH and stress‑related upper gastrointestinal bleeding in patients with severe head injury. Dig Dis Sci 40:645–650
24. Cannon LA, Heiselman D, Gardner W, Jones J (1987) Prophylaxis of upper gastrointestinal tract bleeding in mechanically ventilated patients: A randomized study comparing the efficacy of sucralfate, cimetidine, and antacids. Arch Intern Med 147:2101–2106
25. Conrad SA, Gabrielli A, Margolis B, Quartar A, Hata JS, Frank WO, Bagin RG, Rock JA, Hepburn B, Laine L (2005) Randomized, double‑blind compari‑son of immediate‑release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 33:760–765
26. Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, Peters S, Rutledge F, Griffith L, McLellan A, Wood G, Kirby A (1998) A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 338:791–797
27. Darlong V, Jayalakhsmi TS, Kaul HL, Tandon R (2003) Stress ulcer prophy‑laxis in patients on ventilator. Trop Gastroenterol 24:124–128
28. De Azevedo JRA, Soares MDGA, Silva GAE, De Lima Palacio G (2000) Prevention of stress ulcer bleeding in high risk patients. Comparison of three drugs: GED Gastrenterologico Endosc Dig 19:239–244

29. Eddleston JM, Pearson RC, Holland J, Tooth JA, Vohra A, Doran BH (1994) Prospective endoscopic study of stress erosions and ulcers in critically ill adult patients treated with either sucralfate or placebo. Crit Care Med 22:1949–1954

30. Fabian TC, Boucher BA, Croce MA, Kuhl DA, Janning SW, Coffey BC, Kudsk KA (1993) Pneumonia and stress ulceration in severely injured patients. A prospective evaluation of the effects of stress ulcer prophylaxis. Arch Surg 128:185–191

31. Fink M, Karlstadt RG, Maroko RT, Field B (2003) Intravenous pantoprazole (VP) and continuous infusion cimetidine (C) prevent upper gastrointestinal bleeding (UGIB) regardless of APSSII score (APACHE II) in high risk intensive care unit (ICU) patients. Gastroenterology 124:A625–A626

32. Fogas JF, Kiss GK, Gyura FG, Tobias ZT, Molnar ZM, (2013) Effects of proton pump inhibitor versus H2-receptor antagonist stress ulcer prophylaxis on ventilator-associated pneumonia: a pilot study. 33rd International Symposium on Intensive Care and Emergency Medicine Brussels Belgium 17:S150–S151

33. Friedman CJ, Oblinger MJ, Suratt PM, Bowers J, Goldberg SK, Sperling MH, Blitzer AH (1982) Prophylaxis of upper gastrointestinal hemorrhage in patients requiring mechanical ventilation. Crit Care Med 10:316–319

34. Groll A, Simandl V, Vogel RD, Taguchi K, Todd RJ, Depuy WT (1986) Cimetidine prophylaxis for gastrointestinal bleeding in an intensive care unit. Gut 27:135–140

35. Halloran LG, Zlass AM, Gayle WE, Wheeler CB, Miller JD (1980) Prevention of acute gastrointestinal complications after severe head injury: a controlled trial of cimetidine prophylaxis. Am J Surg 139:44–48

36. Hanisch EW, Encke A, Naujoks F, Windolf J (1998) A randomized, double-blind trial for stress ulcer prophylaxis shows no evidence of increased pneumonia. Am J Surg 176:453–457

37. Harlaftis N, Basdanis G, Papapolychroniadis C, Prousalidis J, Apostolidis S, Korndis C, Avramidou F, Katsios C (1997) Nosocomial pneumonia in mechanically ventilated patients during stress ulcer prophylaxis with sucralfate and ranitidine. Hellen J Gastroenterol 10:230–235

38. Hata M, Shiono M, Sekino H, Furukawa H, Sezai A, Iida M, Yoshitake I, Hattori T, Wakui S, Soeda M, Taoka M, Negishi N, Sezai Y (2005) Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery. Circ J 69:331–334

39. Kantorova I, Svoboda P, Schmer P, Dehdashti F, Ataei B (2016) Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Gastroenterology 124:A625–A626

40. Karlstadt RG, Iberti TJ, Silverstein J, Lindenberg L, Right-Asare P, Rockhold FW (1993) Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med 21:19–30

41. Levy MJ, Seelig CB, Robinson NJ, Ranney JE (1997) Comparison of sucralfate versus ranitidine. Anaesthesist 37:704–710

42. Martin LF, Booth FV, Karlstadt RG, Silverstein JH, Jacobs DM, Hampsey J, Bowman SC, D’Ambrosia CA, Rockhold FW (1993) Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med 21:19–30

43. Metz CA, Livingston DH, Smith JS, Larson GM, Wilson TH (1993) Impact of multiple risk factors and ranitidine prophylaxis on the development of stress-related upper gastrointestinal bleeding: a prospective, multicenter, double-blind, randomized trial. The Ranitidine Head Injury Study Group. Crit Care Med 21:1844–1849

44. Misra UK, Kalita J, Pandey S, Mandal SK, Srivastava M (2005) A randomized placebo controlled trial of ranitidine versus sucralfate in patients with spontaneous intracerebral hemorrhage for prevention of gastric hemorrhage. J Neurosurg 239:5–10

45. Mustafa NA, Akturk G, Ozdemir B, Koksal I, Erçay S, Solak M (1995) Acute stress bleeding prophylaxis with sucralfate versus ranitidine and incidence of secondary pneumonia in intensive care unit patients. Intensive Care Med 21:287

46. Pan X, Zhang W, Li Z, Xu G, Yin N, Wang D, Shi X (2004) The preventive effects of rabeprazole on upper gastrointestinal tract hemorrhage in patients with severe acute pancreatitis. Chin J Gastroenterol 9:30–32

47. Pickworth KK, Falcone RE, Hoogeboom JE, Santanello SA (1993) Occurrence of nosocomial pneumonia in mechanically ventilated trauma patients: a comparison of sucralfate and ranitidine. Crit Care Med 21:1856–1862

48. Powell H, Morgan M, Li SK, Baron JH (1993) Inhibition of gastric acid secretion in the intensive care unit after coronary artery bypass graft. A pilot control study of intravenous omeprazole by bolus and infusion, ranitidine and placebo. Theor Surg 8:125–130

49. Prakash S, Rai A, Gogia AR, Prakash S (2008) Nosocomial pneumonia in mechanically ventilated patients receiving ranitidine or sucralfate as stress ulcer prophylaxis. Indian J Anaesth 52:179–184

50. Reusser P, Gyr K, Scheidegger D, Buchmann B, Zimmerli W (1990) Nosocomial pneumonia during stress ulcer prophylaxis with cimetidine and sucralfate versus ranitidine. Arch Ges Gastroenterol 22:1949–1954

51. Reusser P, Gyr K, Scheidegger D, Buchmann B, Zimmerli W (1990) Nosocomial pneumonia during stress ulcer prophylaxis with cimetidine and sucralfate versus ranitidine. Arch Gastroenterol 22:1949–1954

52. Metz CA, Livingston DH, Smith JS, Larson GM, Wilson TH (1993) Impact of multiple risk factors and ranitidine prophylaxis on the development of stress-related upper gastrointestinal bleeding: a prospective, multicenter, double-blind, randomized trial. The Ranitidine Head Injury Study Group. Crit Care Med 21:1844–1849

53. Phillips JO, Metzler MH, Huckfeld RE, Olsen K (1998) A multicenter, prospective, randomized clinical trial of continuous infusion IV ranitidine vs. omeprazole suspension in the prophylaxis of stress ulcers. Crit Care Med 26:101A

54. Pickworth KK, Falcone RE, Hoogeboom JE, Santanello SA (1993) Occurrence of nosocomial pneumonia in mechanically ventilated trauma patients: a comparison of sucralfate and ranitidine. Crit Care Med 21:1856–1862

55. Powell H, Morgan M, Li SK, Baron JH (1993) Inhibition of gastric acid secretion in the intensive care unit after coronary artery bypass graft. A pilot control study of intravenous omeprazole by bolus and infusion, ranitidine and placebo. Theor Surg 8:125–130

56. Prakash S, Rai A, Gogia AR, Prakash S (2008) Nosocomial pneumonia in mechanically ventilated patients receiving ranitidine or sucralfate as stress ulcer prophylaxis. Indian J Anaesth 52:179–184

57. Prod’Hom C, Leuenberger P, Koerfer J, Blum A, Chiorero R, Schallor MD, Perret C, Spinelli O, Blondel J, Siegent H, Saghafi L, Blanc D, Francioli P (1994) Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 120:663–662

58. Reusser P, Gyr K, Scheidegger D, Buchmann B, Buser M, Zimmerli W (1990) Prospective endoscopic study of stress erosions and ulcers in critically ill neurological patients: current incidence and effect of acid-reducing prophylaxis. Crit Care Med 18:270–274

59. Risaliti A, Terrosu G, Uzzau A, Petri R, Intini S, Carrofi P, Noce L, Anania G, Cenedoli C, Sor P (1993) Intravenous omeprazole vs ranitidine in the prophylaxis of stress ulcers. Acta Chirurgica Italica 49:397–401

60. Ruiz-Santana S, Ortiz E, Gonzalez B, Bolanos J, Ruiz-Santana AJ, Manzano LM, Santiago LA, Martin LF, Booth FV, Karlstadt RG, Silverstein JH, Jacobs DM, Hampsey J, Bowman SC, D’Ambrosia CA, Rockhold FW (1993) Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med 21:19–30

61. Ryan P, Dawson J, Teres D, Celoria G, Navab F (1993) Nosocomial pneumonia during stress ulcer prophylaxis with cimetidine and sucralfate. Arch Surg 128:1353–1357

62. Selvanderan SP, Summers MJ, Finnis ME, Slummer MP, Ali Abdelhamid Y, Anderson MB, Chapman JM, Rayner CK, Deane AM (2016) Pantoprazole
or placebo for stress ulcer prophylaxis (POP-UP): randomized double-blind exploratory study. Crit Care Med 44:1842–1850
67. Simms HH, De Maria E, McDonald L, Peterson D, Robinson A, Burchard KW (1991) Role of gastric colonization in the development of pneumonia in critically ill trauma patients: results of a prospective randomized trial. J Trauma 31:531–536
68. Solouki M, Mar'ashian SM, Kouchak M, Nasiri A, Mokhtari M, Amipour A (2009) Ventilator-associated pneumonia among ICU patients receiving mechanical ventilation and prophylaxis of gastrointestinal bleeding. Iran J Clinical Infect Dis 4:177–180
69. Solouki M, Marashian SM, Kouchari M, Mokhtari M, Nasiri E (2009) Comparison between the preventive effects of ranitidine and omeprazole on upper gastrointestinal bleeding among ICU patients. Tanaffos 8:37–42
70. Somberg L, Morris J Jr, Fantus R, Grabhoefer P, Seifert V, Torok M (1984) Prevention of acute stress hemorrhages of the upper gastrointestinal tract with pirenzepine and antacids. A controlled comparison between pirenzepine and cimetidine. Anaest Intensivther Notfallmed 19:240–244
71. van den Berg B, van Blankenstein M (1985) Prevention of stress-related mucosal disease. J Trauma 64:1202–1210
72. Thomason MH, Payseur ES, Hakenewerth AM, Norton HJ, Mehta B, Reeves TR, Moore-Swartz MW, Robbins PI (1996) Nosocomial pneumonia in ventilated trauma patients during stress ulcer prophylaxis with sucralfate, antacid, and ranitidine. J Trauma 41:503–508
73. Tryba M, Zevounou F, Grabhoefer P, Seifert V, Torok M (1984) Prevention of acute stress hemorrhages of the upper gastrointestinal tract with pirenzepine and antacids. A controlled comparison between pirenzepine and cimetidine. Anaest Intensivther Notfallmed 19:240–244
74. van den Berg B, van Blankenstein M (1985) Prevention of stress-induced upper gastrointestinal bleeding by cimetidine in patients on assisted ventilation. Digestion 31:1–8
75. Wee B, Liu CH, Cohen H, Krakutsch S, Reddy K, Mukherji R (2013) 731: IV Famotidine vs. IV Pantoprazole for stress ulcer prevention in the ICU: a prospective Study. Crit Care Med 41:A181
76. Zinner MJ, Zuidema GD, Smith P, Mignosa M (1981) The prevention of upper gastrointestinal tract bleeding in patients in an intensive care unit. Surg Gynecol Obstet 153:214–220
77. Giuliano C, Wilhelm SM, Kale-Pradhan PB (2012) Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 5:337–344
78. Johnstone J, Nerenberg K, Loeb M (2010) Meta-analysis: proton pump inhibitors in human gastric juice. Am J Med 83:125–127
79. Herzig SJ, Howell MD, Ngo LH, Marcantionio ER (2009) Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 301:2120–2128
80. MacLaren R, Kassel LE, Kiser TH, Fish DN (2015) Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events. Expert Opin Drug Saf 14:269–280
81. Alshamsi F, Belley-Cote E, Almenawer SA, Alqahtani Z, Perri D, Alshamsi F, Almenawer S, Jaeschke R, MacLaren R, Alhazzani W (2017) Sucralfate versus histamine 2 receptor antagonists for stress ulcer prophylaxis in adult critically ill patients: a meta-analysis and trial sequential analysis of randomized trials. J Crit Care 40:21–30
82. Alshamsi F, Belley-Cote E, Cook D, Almenawer SA, Alqahtani Z, Perri D, Thabane L, Al-Omari A, Lewis K, Guyatt G, Alhazzani W (2016) Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care 20:120
83. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR (2005) How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 24:2401–2428
84. Nair GB, Niederman MS (2015) Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med 41:34–48
85. Huang J, Cao Y, Liao C, Wu L, Gao F (2010) Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials. Crit Care 14:R194
86. Barkun AN, Adam V, Martel M, Bardou M (2013) Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists. Value Health 16:14–22
87. MacLaren R, Reynolds PM, Allen RR (2014) Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med 174:564–574
88. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR (2005) How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 24:2401–2428
89. Nair GB, Niederman MS (2015) Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med 41:34–48
90. MacLaren R, Reynolds PM, Allen RR (2014) Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med 174:564–574